| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers C > Headlines for ChondroGene Ltd. > News item |
ChondroGene: Study shows Sentinel Principal identifies biomarkers for osteoarthritis
By E. Janene Geiss
Philadelphia, Oct. 25 - ChondroGene Ltd. announced Tuesday that its study of its Sentinel Principal for the discovery of blood-based biomarkers was able to identify patients with early-stage, asymptomatic osteoarthritis.
The study identified 3,543 genes in the blood that are expressed differently in patients with mild osteoarthritis. This is the first time that a gene expression blood test has been shown to detect asymptomatic osteoarthritis in patients, officials said in a company news release.
The findings are outlined in a paper entitled, "Blood-based biomarkers for detecting mild osteoarthritis in the human knee," which has been published in the October issue of "Osteoarthritis and Cartilage."
In March 2005, ChondroGene received support from National Research Council Canada Industrial Research Assistance Program to assist in the development of an asymptomatic osteoarthritis diagnostic, based on the Sentinel Principle, which detects and stages virtually any disease or medical condition from a blood sample, officials said.
The eventual commercial product is expected to be able to identify patients, stage severity of disease, monitor progression and response to therapy, officials said.
In the area of arthritis, ChondroGene also has a collaboration with Pfizer Inc. to use the Sentinel Principle to identify blood-based biomarkers for use in their asymptomatic osteoarthritis drug development programs, officials said.
ChondroGene is a Toronto-based biotechnology company focused on the application of functional genomics to enable early diagnosis of disease through biomarkers.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.